Jing Zhou Hou
Hematology & Oncology · Pittsburgh, PANPI 1053478131
Payments from drug & device makers
Across 752 payments — averaging $15,770 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$4.8M
- Beigene, Ltd.$2.4M
- AbbVie$2.2M
- Beone Medicines Ltd.$704K
- Acerta Pharma LLC$553K
- Janssen Research & Development, LLC$462K
- plus $760K from 25 others
Across 5 payments — averaging $524.40 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- F. Hoffmann-la Roche AG$3K
- AbbVie$88
What the payments were for
- Consulting fees$62,14079%
- Speaking & faculty fees$7,53810%
- Travel & lodging$2,9184%
- Food & beverage$5,7997%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 50 | $4,806,441 |
| Beigene, Ltd. | 50 | $2,350,345 |
| AbbVie | 298 | $2,223,462 |
| Beone Medicines Ltd. | 23 | $704,020 |
| Acerta Pharma LLC | 16 | $552,585 |
| Janssen Research & Development, LLC | 47 | $462,070 |
| Beigene AUS Pty Ltd | 147 | $379,458 |
| Beone Medicines USA, Inc. | 20 | $67,240 |
| Genentech, Inc. | 24 | $64,947 |
| Pharmacyclics LLC, An Abbvie Company | 23 | $53,118 |
| Novartis | 4 | $41,362 |
| Epizyme, Inc. | 6 | $37,047 |
| Trillium Therapeutics USA, LLC | 1 | $29,635 |
| Eli Lilly | 5 | $28,994 |
| Exelixis Inc. | 1 | $28,600 |
| Beigene USA, Inc. | 13 | $12,706 |
| Verastem, Inc. | 2 | $6,062 |
| Aptevo Therapeutics Inc | 1 | $3,188 |
| Genentech USA, Inc. | 3 | $2,847 |
| Karyopharm Therapeutics Inc. | 1 | $1,600 |
| Secura Bio, Inc. | 2 | $1,598 |
| Genmab U.S., Inc. | 4 | $483 |
| Eagle Pharmaceuticals, Inc. | 1 | $149 |
| Bristol Myers Squibb | 1 | $138 |
| Rigel Pharmaceuticals, Inc. | 2 | $136 |
| Eisai Inc. | 1 | $120 |
| Gilead | 2 | $111 |
| Johnson & Johnson | 1 | $106 |
| Abbott | 1 | $74 |
| Lilly USA, LLC | 1 | $27 |
| Merz Pharmaceuticals, LLC | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,858,686 in reported general payments places this provider in the 95th percentile of 682 hematology & oncology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VenclextaVenetoclax | 90 | $727,952 |
| JakafiRuxolitinib Phosphate | 44 | $640,502 |
| PomalystPomalidomide | 21 | $483,708 |
| JaypircaPirtobrutinib | 12 | $267,775 |
| CalquenceAcalabrutinib Maleate | 12 | $195,660 |
| Imatinib Mesylate | 31 | $89,560 |
| EliquisApixaban | 57 | $59,619 |
| Cyclosporine | 31 | $18,260 |
| XareltoRivaroxaban | 11 | $12,499 |
| Tacrolimus | 16 | $6,229 |
| Anagrelide Hcl | 12 | $1,888 |
| Acyclovir | 82 | $1,810 |
| Allopurinol | 127 | $1,270 |
| Hydroxyurea | 48 | $941 |
| Dexamethasone | 31 | $550 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVenclexta | $2,223,462 | $727,95290 claims |
| Lilly USA, LLCJaypirca | $27 | $267,77512 claims |
| AstraZenecaCalquence | $4,806,441 | $195,66012 claims |
| Johnson & JohnsonXarelto | $106 | $12,49911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 682 hematology & oncology providers in Pennsylvania.
Other hematology & oncology in Pittsburgh
- Diwakar DavarPittsburgh$21.6M
- Jason LukePittsburgh$15M
- Leonard ApplemanPittsburgh$12.8M
- Taofeek OwonikokoPittsburgh$9.7M
- Ahmad TarhiniPittsburgh$7.4M
- Samuel JacobsPittsburgh$6.5M
- Cyrus KhanPittsburgh$4.5M
- Kathleen DorritiePittsburgh$3.2M
- Salman FazalPittsburgh$2.9M
- Mounzer AghaPittsburgh$2.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.